Therapeutic potential of topical administration of siRNAs against HIF-1α for corneal neovascularization
- PMID: 35367249
- DOI: 10.1016/j.exer.2022.109036
Therapeutic potential of topical administration of siRNAs against HIF-1α for corneal neovascularization
Abstract
Given the implications of the problem of neovascularization on ocular health, as well as the growth in the number of cases, the purpose of the present study has been testing the efficacy of siRNAs (small interfering RNA) designed to silence Hypoxia Inducible Factor -1α (HIF-1α) and to demonstrate that their use stops neovascularization in a model of corneal burn. Corneal wounds in the limbic zone were made in the eyes of New Zealand white rabbits. Topical applications of siRNAs were done the next day to the wound for four consecutive days and eyes were examined with a slit lamp. Evaluation of neovascularization progress was done by analyzing images by ImageJTM and to determine the neovascular area in Matlab ® was used. At the same time, a rabbit corneal cell line was used for in vitro study of hypoxia exposure and Western blot analysis of the cell's extracts were done. Under normal cell culture oxygenation, the expression of HIF-1α was lower than that observed under hypoxic conditions. After 2 h of hypoxia, there was a significant increase in the HIF-1α expression, effect that was maintained up to 6 h. The increased in HIF-1α was mimicked by a cell permeable prolyl-4-hydroxylase inhibitor. Cobalt chloride showed no capacity to increase HIF-1α in vitro. The effect of three different siRNA on HIF-1α was tested after 4 h of hypoxia. siRNA#1 was able to silence 80% of HIF-1α expression, siRNA#2 and siRNA#3 reduce the expression in 45% and 40% respectively. In addition, the three siRNA were tested in a corneal model of neovascularization. scrambledsiRNA#2 was the most effective inhibitor of blood vessel production, followed by siRNA#3 and siRNA#1. Compared to the scrambled siRNA (100% of blood vessel generation), siRNA#2 blocked the presence of blood vessels by 83 ± 2%, siRNA#3 inhibited 45 ± 7% and siRNA#1 only inhibited 18 ± 5%. The necessary time to observe the 50% of effect showed values of NV50 of 10.2 ± 2.4 days for the scrambled siRNA, 9.1 ± 1.4 for siRNA#1, 6.5 ± 1.85 for siRNA#2 and 4.8 ± 1.8 days for siRNA#3. In conclusion, the topical application of siRNA towards HIF-1α seems to be an effective and reliable method to stop neovascularization.
Keywords: Blood vessel; Cornea; HIF-1α; Hypoxia; Neovascularization; siRNA.
Copyright © 2022. Published by Elsevier Ltd.
Similar articles
-
Inhibition of VEGF expression and corneal neovascularization by shRNA targeting HIF-1α in a mouse model of closed eye contact lens wear.Mol Vis. 2012;18:864-73. Epub 2012 Apr 6. Mol Vis. 2012. PMID: 22511848 Free PMC article.
-
Inhibited corneal neovascularization in rabbits following corneal alkali burn by double-target interference for VEGF and HIF-1α.Biosci Rep. 2019 Jan 30;39(1):BSR20180552. doi: 10.1042/BSR20180552. Print 2019 Jan 31. Biosci Rep. 2019. Retraction in: Biosci Rep. 2024 Jun 26;44(6):BSR-2018-0552_RET. doi: 10.1042/BSR-2018-0552_RET. PMID: 30355648 Free PMC article. Retracted.
-
[Inhibitory effect of interfering RNA targeting HIF-1alpha and VEGF on retinal neovascularization in the mouse].Zhonghua Yan Ke Za Zhi. 2008 Oct;44(10):921-8. Zhonghua Yan Ke Za Zhi. 2008. PMID: 19176122 Chinese.
-
Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF.J Cell Physiol. 2009 Jan;218(1):66-74. doi: 10.1002/jcp.21566. J Cell Physiol. 2009. PMID: 18767037
-
Hypoxia-inducible factor-1α: A promising therapeutic target for vasculopathy in diabetic retinopathy.Pharmacol Res. 2020 Sep;159:104924. doi: 10.1016/j.phrs.2020.104924. Epub 2020 May 25. Pharmacol Res. 2020. PMID: 32464323 Review.
Cited by
-
Detailed protocol for a corneal thermal cauterization-based (lymph-)angiogenesis assay in mice.MethodsX. 2023 Oct 17;11:102446. doi: 10.1016/j.mex.2023.102446. eCollection 2023 Dec. MethodsX. 2023. PMID: 37928105 Free PMC article.
-
Pharmacotherapy and Nutritional Supplements for Neovascular Eye Diseases.Medicina (Kaunas). 2023 Jul 20;59(7):1334. doi: 10.3390/medicina59071334. Medicina (Kaunas). 2023. PMID: 37512145 Free PMC article. Review.
-
Available Therapeutic Options for Corneal Neovascularization: A Review.Int J Mol Sci. 2024 May 17;25(10):5479. doi: 10.3390/ijms25105479. Int J Mol Sci. 2024. PMID: 38791518 Free PMC article. Review.
-
Therapeutic potential of topical administration of acriflavine against hypoxia-inducible factors for corneal fibrosis.Front Pharmacol. 2022 Oct 21;13:996635. doi: 10.3389/fphar.2022.996635. eCollection 2022. Front Pharmacol. 2022. PMID: 36339559 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources